COMMUNIQUÉS West-GlobeNewswire

VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer
03/06/2019
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03) CA-125 response (GCIG) was reported in 58% of evaluable patients and was [...]
Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity
03/06/2019
TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 [...]
Scapa Healthcare Opens New Medical Device Manufacturing Facility in Knoxville, TN
03/06/2019
Opening Ribbon Cutting Ceremony Held June 3rd, 2019 WINDSOR, Conn., June 03, 2019 (GLOBE NEWSWIRE) -- Scapa Healthcare , the trusted strategic partner of choice to the world’s leading companies in advanced wound care, [...]
Imagin Medical to Report Second Fiscal Quarter 2019 Financial Results on June 11, 2019 – Conference Call to Follow
03/06/2019
VANCOUVER, British Columbia and BOSTON, June 03, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the [...]
Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
03/06/2019
LEXINGTON, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the [...]
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage
03/06/2019
ANDOVER, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, [...]
Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions
03/06/2019
New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration Data CHICAGO, June 03, 2019 (GLOBE NEWSWIRE) -- 2019 ASCO Annual Meeting – Cellworks Group, Inc., a leader in Precision Medicine and [...]
Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
03/06/2019
-- 5F9 Well Tolerated with Clinical Activity as Monotherapy and in Combination with Azacitidine -- -- CR Rate of 55% and ORR of 100% Observed in Patients with Higher-Risk MDS -- -- CR/CRi Rate of 50% and ORR of 64% [...]
Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference
03/06/2019
CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively [...]
Afrezza® (insulin human) Inhalation Powder Approved in Brazil
03/06/2019
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. The innovative delivery system reduces injections while improving glycemic control in adult patients with diabetes [...]
Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
03/06/2019
ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today [...]
Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® (ivosidenib) in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
03/06/2019
– With Longer Follow Up, CR+CRh Rate Increased to 70% and CR Rate Increased to 61% in the Phase 1 Study of TIBSOVO ® in Combination with Azacitidine – – Phase 1 Data of Single Agent TIBSOVO ® Demonstrated 12.6 Month [...]
Progenics Pharmaceuticals Mails Letter to Shareholders
03/06/2019
Asks Shareholders to Vote “FOR” All the Company’s Qualified Directors on the WHITE Proxy Card NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an [...]
Neon Therapeutics to Present at Jefferies 2019 Healthcare Conference
03/06/2019
CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief [...]
Immutep Presentation at ASCO 2019
03/06/2019
SYDNEY, Australia, June 03, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Humanigen to Present at the Jefferies 2019 Healthcare Conference
03/06/2019
BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered ® monoclonal antibodies focused on [...]
AIT Therapeutics to Participate at Jefferies 2019 Global Healthcare Conference
03/06/2019
GARDEN CITY, N.Y. and REHOVOT, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ( [...]
Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010
03/06/2019
CRANBURY, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic [...]
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts
03/06/2019
TM-B1 demonstrates 80% accuracy vs. 50% accuracy for current gold standard Todos Medical to attend 2019 ASCO Annual Meeting in Chicago, IL REHOVOT, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: [...]

Pages